Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 11NET 7Thoracic 2Tumor-Agnostic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Primary Inoperable Thymoma 1Pleural Effusion 1Lymphangiomyoma 1Lymphangioleiomyomatosis 1Chylous Ascites 1Chylothorax 1Ascites 1

Interventions

Carboplatin 335Pemetrexed 276Cisplatin 228Paclitaxel 193pembrolizumab 178Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Nivolumab 112Bevacizumab 112Radiotherapy 84Etoposide 68durvalumab 62atezolizumab 59Ipilimumab 51Radiosurgery 49osimertinib 42130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Octreotide × Thoracic × Clear all
NCT02021942 2018-02-05

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

University of Regensburg

Phase 2 Completed
16 enrolled 11 charts
Thoracic

Primary Inoperable Thymoma

NCT00005906 2010-04-30

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
4 enrolled 8 charts
Thoracic

Ascites, Chylous Ascites, Chylothorax, Lymphangiomyoma, Pleural Effusion, Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡